

Ann I McCormack

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3764663/publications.pdf>

Version: 2024-02-01

50
papers

1,976
citations

394421

19
h-index

265206

42
g-index

53
all docs

53
docs citations

53
times ranked

1560
citing authors

#	ARTICLE	IF	CITATIONS
1	Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. <i>Pituitary</i> , 2022, 25, 64-73.	2.9	7
2	Editorial: Refractory Pituitary Adenoma—Current Challenges and Emerging Treatments. <i>Frontiers in Endocrinology</i> , 2022, 13, 868174.	3.5	3
3	MEN4, the MEN1 Mimicker: A Case Series of three Phenotypically Heterogenous Patients With Unique <i>CDKN1B</i> Mutations. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 2339-2349.	3.6	14
4	Low but not undetectable early postoperative nadir serum cortisol predicts sustained remission in Cushing's disease. <i>Endocrine Oncology</i> , 2022, , .	0.4	0
5	Multidisciplinary Team Care in the Surgical Management of Pituitary Adenoma. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2021, 82, 295-302.	0.8	5
6	Towards precision medicine for clinically nonfunctioning pituitary tumours. <i>Clinical Endocrinology</i> , 2021, 95, 398-409.	2.4	5
7	Childhood-onset prolactinomas—Should earlier surgery be considered?. <i>Clinical Endocrinology</i> , 2021, 95, 571-573.	2.4	1
8	Transcription factor immunohistochemistry in the diagnosis of pituitary tumours. <i>European Journal of Endocrinology</i> , 2021, 184, 891-901.	3.7	19
9	Assessment of magnetic resonance imaging criteria for the diagnosis of cavernous sinus invasion by pituitary tumors. <i>Journal of Clinical Neuroscience</i> , 2021, 90, 262-267.	1.5	1
10	Consensus on diagnosis and management of Cushing's disease: a guideline update. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 847-875.	11.4	315
11	Letter to the Editor From Raven et al: Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccination. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, , .	3.6	19
12	Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e108-e118.	3.6	45
13	Long-Term Sinonasal Function Following Transnasal Pituitary Surgery: A Comparison of Surgical Approach. <i>American Journal of Rhinology and Allergy</i> , 2020, 34, 361-368.	2.0	8
14	Outcomes of pituitary surgery for Cushing's disease: a systematic review and meta-analysis. <i>Pituitary</i> , 2020, 23, 595-609.	2.9	44
15	Are aggressive pituitary tumors and carcinomas two sides of the same coin? Pathologists reply to clinician's questions. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 243-251.	5.7	30
16	Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic—an international perspective. <i>Pituitary</i> , 2020, 23, 327-337.	2.9	49
17	Temozolomide therapy for aggressive pituitary tumours—current understanding and future perspectives. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 263-276.	5.7	21
18	Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature—Are We There Yet? <i>Cancers</i> , 2020, 12, 308.	3.7	23

#	ARTICLE	IF	CITATIONS
19	MANAGEMENT OF ENDOCRINE DISEASE: Does gender matter in the management of acromegaly?. European Journal of Endocrinology, 2020, 182, R67-R82.	3.7	37
20	Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. Frontiers in Endocrinology, 2020, 11, 576027.	3.5	20
21	Fatal high-grade skull osteosarcoma 30 years following radiotherapy for Cushing's disease. Endocrinology, Diabetes and Metabolism Case Reports, 2020, 2020, .	0.5	0
22	Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases. Journal of Physical Education and Sports Management, 2019, 5, a003764.	1.2	7
23	Development and validation of a targeted gene sequencing panel for application to disparate cancers. Scientific Reports, 2019, 9, 17052.	3.3	18
24	Diagnosing Cushing's disease in the context of chronic kidney disease: a case report and literature review. European Journal of Endocrinology, 2019, 181, K29-K35.	3.7	6
25	Aggressive pituitary tumours and carcinomas: two sides of the same coin?. European Journal of Endocrinology, 2018, 178, C7-C9.	3.7	54
26	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	3.7	196
27	Malignant transformation in non-functioning pituitary adenomas (pituitary carcinoma). Pituitary, 2018, 21, 217-229.	2.9	37
28	European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. European Journal of Endocrinology, 2018, 178, G1-G24.	3.7	387
29	A perfect storm: towards reducing the risk of suicide in the medical profession. Medical Journal of Australia, 2018, 209, 378-379.	1.7	3
30	A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly. European Journal of Endocrinology, 2018, 179, 97-108.	3.7	27
31	Germline variants in familial pituitary tumour syndrome genes are common in young patients and families with additional endocrine tumours. European Journal of Endocrinology, 2017, 176, 635-644.	3.7	33
32	Prolactin correction for adequacy of petrosal sinus cannulation may diminish diagnostic accuracy in Cushing's disease. Clinical Endocrinology, 2017, 87, 515-522.	2.4	19
33	How useful is urinary-free cortisol in the clinic?. Biomarkers in Medicine, 2017, 11, 1009-1016.	1.4	5
34	Optimising pituitary surgery outcomes in Australia: how much does size matter?. Internal Medicine Journal, 2017, 47, 1225-1227.	0.8	1
35	Corticotrophin-releasing hormone (<sc>CRH</sc>) expression in the dermoid component of ovarian teratomas. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 867-869.	2.4	0
36	Ectopic Cushing syndrome due to neuroendocrine prostatic cancer. Internal Medicine Journal, 2016, 46, 630-632.	0.8	5

#	ARTICLE	IF	CITATIONS
37	Cutaneous lichen amyloidosis in multiple endocrine neoplasia. Internal Medicine Journal, 2016, 46, 116-117.	0.8	2
38	Pituitary hyperplasia: case series and literature review of an under-recognised and heterogeneous condition. Endocrinology, Diabetes and Metabolism Case Reports, 2015, 2015, 150017.	0.5	20
39	Confusing genes: a patient with MEN2A and Cushing's disease. Clinical Endocrinology, 2013, 78, 966-968.	2.4	30
40	MGMT expression and pituitary tumours: relationship to tumour biology. Pituitary, 2013, 16, 208-219.	2.9	18
41	Atypical pituitary adenomas – investigation and validation of the 2004 WHO criteria. Pathology, 2013, 45, S83-S84.	0.6	0
42	Medication to prevent breast cancer – too much to swallow?. Medical Journal of Australia, 2012, 196, 314-314.	1.7	2
43	Temozolomide in the Treatment of Aggressive Pituitary Tumours - An Overview of Existing Knowledge and Future Perspectives. European Neurological Review, 2012, 7, 228.	0.5	0
44	Temozolomide in the Treatment of Aggressive Pituitary Tumours – An Overview of Existing Knowledge and Future Perspectives. US Endocrinology, 2012, 08, 112.	0.3	0
45	Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. European Journal of Clinical Investigation, 2011, 41, 1133-1148.	3.4	139
46	Using the ISBAR handover tool in junior medical officer handover: a study in an Australian tertiary hospital. Postgraduate Medical Journal, 2011, 87, 340-344.	1.8	80
47	Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. European Journal of Endocrinology, 2010, 163, 843-851.	3.7	86
48	Temozolomide in the Treatment of Aggressive Pituitary Tumours – An Overview of Existing Knowledge and Future Perspectives. European Endocrinology, 2010, 8, 116.	1.5	0
49	Low O ⁶ -methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clinical Endocrinology, 2009, 71, 226-233.	2.4	125
50	Use of temozolomide in a large cohort of patients with aggressive pituitary tumours and pituitary carcinomas: Results from a European Society of Endocrinology (ESE) survey. Endocrine Abstracts, 0, , .	0.0	10